By Andrea Figueras
Roche Holding announced that the U.S. Food and Drug Administration (FDA) has granted approval for Xolair, making it the first medication approved for both children and adults to decrease allergic reactions to multiple foods.
The FDA's approval is based on compelling data obtained from a study involving patients between the ages of one and 55, according to an announcement from the Swiss pharmaceutical company on Friday.
Results from the study revealed that a significantly higher percentage of food-allergy patients treated with Xolair were able to tolerate small quantities of peanuts, milk, eggs, and cashews without experiencing any allergic reactions. This is in stark contrast to individuals who were treated solely with a placebo, Roche explained.
Roche emphasizes that individuals utilizing Xolair for food allergies should continue avoiding all foods they have allergies to. While the drug is designed to alleviate allergic reactions, including anaphylaxis, which may arise from accidental exposure to these foods, it should not be utilized as emergency treatment for any allergic reactions.
Furthermore, Roche is pleased to announce that Xolair is widely accessible and can now be prescribed throughout the United States.
Related Articles
BridgeBio Pharma Inc. Reports Positive Results in Late-Stage Trial
BridgeBio Pharma Inc. reports positive results in a late-stage trial for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The trial achieves sta...
Investigation Underway for Fatal Crash Involving Tesla in Virginia
The National Highway Traffic Safety Administration is examining a fatal Tesla crash in Virginia, adding to the 35 accidents involving Tesla vehicles under inves...
Tim Scott's Economic Plan
Senator Tim Scott is proposing an economic plan focused on tax cuts to stimulate the economy and create jobs. His plan includes cutting spending, relocating age...